Your Best Stock
$148.59
+$0.51 (+0.34%)
Market open · Sep 24, 2:00 pm ET
After hours $148.00 -0.05%
Open$148.28
Prev close$148.08
Day range$148.01 – $151.46
Volume2.95M
Market cap$366.60B
P/E (TTM)118.9
Dividend yield2.26%

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$16.61B+5.1% YoY
Operating profit-$433.00M-107.8% YoY
Net profit-$1.34B-130.2% YoY
Diluted EPS-$0.54-130.7% YoY
Free cash flow$4.48B+77.0% YoY
Operating cash flow$5.37B

Revenue, last 8 quarters

$16.7BSep '24$15.6BDec '24$15.5BMar '25$15.8BJun '25$17.3BSep '25$16.4BDec '25$16.3BMar '26$16.6BJun '26

Net profit, last 8 quarters

$3.2BSep '24$3.7BDec '24$5.1BMar '25$4.4BJun '25$5.8BSep '25$3.0BDec '25$-4.2BMar '26$-1.3BJun '26

Diluted EPS by quarter

1.24Sep '241.48Dec '242.01Mar '251.76Jun '252.32Sep '251.19Dec '25-1.72Mar '26-0.54Jun '26

Free cash flow by quarter

$8.5BSep '24$2.5BDec '24$1.2BMar '25$2.5BJun '25$6.8BSep '25$1.8BDec '25$2.9BMar '26$4.5BJun '26

Annual revenue

$41.5BFY20$48.7BFY21$59.3BFY22$60.1BFY23$64.2BFY24$65.0BFY25

Profitability & balance sheet

Gross margin73.0%
Operating margin10.5%
Net margin4.8%
Return on equity7.0%
Return on assets2.6%
Return on invested capital4.5%
Current ratio1.32
Liabilities / assets67.7%
Cash & investments$7.14B
Total debt$53.91B
Net cash (debt)-$46.77B
Free cash flow / sales24.1%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Pharmaceutical$14.76B 88.9%
  • Animal health$1.78B 10.7%
  • Other$72.00M 0.4%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $16.61B $16.29B $65.01B $16.40B $17.28B
Total Operating Revenue $16.61B $16.29B $65.01B $16.40B $17.28B
Cost of Revenue $4.40B $4.20B $16.38B $5.55B $3.86B
Gross Profit $12.21B $12.09B $48.63B $10.85B $13.42B
Operating Expense $12.65B $15.29B $26.52B $6.78B $6.87B
Selling and Admin Expenses $2.90B $2.70B $10.73B $2.90B $2.63B
Research & Development $9.74B $12.59B $15.79B $3.89B $4.23B
Operating Profit -$433.00M -$3.20B $22.11B $4.07B $6.55B
Net Non-Operating Interest Income (Expense) -$490.00M -$444.00M -$1.01B -$342.00M -$231.00M
Non-Operating Interest Income $35.00M $35.00M $343.00M $69.00M $96.00M
Non-Operating Interest Expense $525.00M $479.00M $1.36B $411.00M $327.00M
Other Income (Expense) $240.00M $111.00M -$26.00M -$303.00M $422.00M
Gain on Sale of Security $205.00M $130.00M $45.00M -$294.00M $317.00M
Special Income (Charges) -$151.00M -$195.00M -$889.00M -$213.00M -$47.00M
-Less:Restructuring and Mergern & Acquisition $151.00M $195.00M $889.00M $213.00M $47.00M
Other Non-Operating Income (Expenses) $186.00M $176.00M $818.00M $204.00M $152.00M
Pretax Profit -$683.00M -$3.53B $21.07B $3.42B $6.75B
Tax $654.00M $709.00M $2.80B $458.00M $958.00M
Net Profit -$1.34B -$4.24B $18.26B $2.96B $5.79B
Profit from Continuing Operations -$1.34B -$4.24B $18.26B $2.96B $5.79B
Minority Interests -$2.00M -$3.00M $9.00M -$1.00M $2.00M
Net Income to Parent Company -$1.34B -$4.24B $18.25B $2.96B $5.79B
Net Income to Common Stockholders -$1.34B -$4.24B $18.25B $2.96B $5.79B
Basic EPS -$0.54 -$1.72 $7.30 $1.20 $2.32
Diluted EPS -$0.54 -$1.72 $7.28 $1.19 $2.32
Dividend Per Share $0.85 $0.85 $3.28 $0.85 $0.81

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $129.80B $128.69B $136.87B $136.87B $129.55B
Total Current Assets $36.68B $35.02B $43.52B $43.52B $47.56B
Cash and Cash Equivalents & Short-Term Investments $7.14B $5.70B $14.57B $14.57B $18.21B
-Cash and Cash Equivalents $6.85B $5.33B $14.57B $14.57B $18.17B
-Short Term Investments $292.00M $375.00M $0.00 $0.00 $45.00M
Receivables $12.56B $12.21B $11.78B $11.78B $12.12B
-Accounts Receivable $12.56B $12.21B $11.78B $11.78B $12.12B
Inventory $6.21B $6.48B $6.66B $6.66B $6.44B
Other Current Assets $10.77B $10.62B $10.52B $10.52B $10.78B
Total Non-Current Assets $93.12B $93.67B $93.35B $93.35B $81.99B
Net PPE $25.74B $25.43B $25.32B $25.32B $25.64B
-Gross PPE $48.47B $47.72B $47.23B $47.23B $46.24B
-Accumulated Depreciation -$22.73B -$22.29B -$21.91B -$21.91B -$20.61B
Investments and Advances $1.22B $1.11B $956.00M $956.00M $1.12B
-Trading Securities $1.22B – $956.00M $956.00M $1.12B
Goodwill and Other Intangible Assets $46.56B $47.33B $48.26B $48.26B $36.90B
-Goodwill $21.58B $21.58B $21.58B $21.58B $21.59B
-Other Intangible Assets $24.98B $25.75B $26.68B $26.68B $15.31B
Other Non-Current Assets $19.60B $19.81B $18.82B $18.82B $18.33B
Total Liabilities $87.82B $82.75B $84.20B $84.20B $77.64B
Total Current Liabilities $27.73B $26.95B $28.33B $28.33B $28.63B
Payables $10.18B $9.95B $11.27B $11.27B $11.04B
-Accounts Payable $3.83B $3.86B $4.40B $4.40B $4.15B
-Total Tax Payable $4.22B $3.95B $4.73B $4.73B $4.85B
-Dividends Payable $2.13B $2.14B $2.14B $2.14B $2.04B
Current Accrued Expenses $14.73B $14.55B $14.47B $14.47B $16.19B
Short-Term Debt and Capital Lease Obligation $2.83B $2.44B $2.59B $2.59B $1.41B
-Current Debt $2.83B $2.44B $2.59B $2.59B $1.41B
Total Non-Current Liabilities $60.09B $55.81B $55.88B $55.88B $49.01B
Long Term Debt and Capital Lease Obligation $51.08B $46.67B $46.75B $46.75B $39.97B
-Long Term Debt $51.08B $46.67B $46.75B $46.75B $39.97B
Non-Current Deferred Liabilities $1.43B $1.49B $1.44B $1.44B $1.38B
Other Non-Current Liabilities $7.57B $7.64B $7.69B $7.69B $7.66B
Total Equity $41.98B $45.93B $52.66B $52.66B $51.91B
Stockholders' Equity $41.93B $45.88B $52.61B $52.61B $51.85B
Capital Stock $1.79B $1.79B $1.79B $1.79B $1.79B
-Common Stock $1.79B $1.79B $1.79B $1.79B $1.79B
Additional Paid-In Capital $44.95B $45.18B $45.03B $45.03B $44.83B
Retained Earnings $63.27B $66.72B $73.08B $73.08B $72.23B
Less: Treasury Stock $64.13B $63.75B $63.00B $63.00B $61.80B
Gains/Losses Not Affecting Retained Earnings -$3.94B -$4.06B -$4.29B -$4.29B -$5.20B
Minority Interests $51.00M $53.00M $56.00M $56.00M $57.00M
-Available for Sale Securities – – $956.00M $956.00M $1.12B

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $5.37B $3.92B $16.47B $2.86B $7.82B
Net cash flow from continuing operations $5.37B $3.92B $16.47B $2.86B $7.82B
Net Income from Continuing Operations -$1.34B -$4.24B $18.26B $2.96B $5.79B
Gain/Loss from Continuing Operations -$243.00M -$168.00M -$368.00M $195.00M -$374.00M
Depreciation & Depletion & Amortization $1.58B $1.51B $5.84B $2.47B $1.15B
Deferred Tax -$544.00M -$315.00M -$1.67B -$825.00M -$212.00M
Other Non-Cash Items $5.19B $8.56B $511.00M $118.00M -$51.00M
Change in Working Capital $423.00M -$1.61B -$6.98B -$2.32B $1.31B
Net cash flow from investing -$5.60B -$10.21B -$13.74B -$11.20B -$283.00M
Net Cash Flow from Continuing Investing Activities -$5.60B -$10.21B -$13.74B -$11.20B -$283.00M
Capital Expenditure -$893.00M -$991.00M -$4.11B -$1.03B -$987.00M
Net Business Purchase and Sale -$5.84B -$8.78B -$10.04B -$10.04B $0.00
Net Investment Purchase and Sale $1.16B -$374.00M $471.00M $46.00M $575.00M
Net Other Investing Changes -$22.00M -$66.00M -$58.00M -$172.00M $129.00M
Financing Cash Flow $1.76B -$2.98B -$1.92B $4.75B $2.64B
Net Cash Flow from Continuing Financing Activities $1.76B -$2.98B -$1.92B $4.75B $2.64B
Net Issuance Payments Of Debt $4.89B -$79.00M $11.38B $7.85B $6.02B
Net Common Stock Issuance -$757.00M -$874.00M -$5.08B -$1.25B -$1.32B
Cash Dividends Paid -$2.14B -$2.11B -$8.18B -$2.02B -$2.03B
Proceeds from Stock Option Exercised $43.00M $157.00M $92.00M $47.00M $14.00M
Net Other Financing Charges -$270.00M -$80.00M -$131.00M $121.00M -$46.00M
Ending Cash Balance $6.89B $5.40B $14.69B $14.69B $18.26B
Net Change in Cash $1.53B -$9.27B $809.00M -$3.59B $10.18B
Beginning Cash Balance $5.40B $14.69B $13.32B $18.26B $8.07B
Effect of Exchange Rate Changes -$37.00M -$19.00M $563.00M $23.00M $10.00M
Free Cash Flow $4.48B $2.93B $12.36B $1.82B $6.84B
-Change in Receivables – – -$1.09B – –
-Change in Inventory – – -$1.18B – –
-Change in Payables and Accrued Expense – – -$1.59B – –
-Change in Other Current Liabilities – – $195.00M – –
-Change In Other Working Capital – – -$3.31B – –
Scroll to Top